137 related articles for article (PubMed ID: 38581672)
1. Patient characteristics, diagnostic testing, and initial treatment profiles of patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) using a Japanese claims database.
Tokushige N; Hayashi Y; Omura J; Jinnai T; Atsumi T
Mod Rheumatol; 2024 Apr; ():. PubMed ID: 38581672
[TBL] [Abstract][Full Text] [Related]
2. Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis.
Sargent T; Tsang Y; Panjabi S; Funtanilla V; Germack HD; Gauthier-Loiselle M; Manceur AM; Cloutier M; Lefebvre P
Adv Ther; 2023 Nov; 40(11):5037-5054. PubMed ID: 37728697
[TBL] [Abstract][Full Text] [Related]
3. Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review.
Gladue H; Altorok N; Townsend W; McLaughlin V; Khanna D
Semin Arthritis Rheum; 2014 Feb; 43(4):536-41. PubMed ID: 24012044
[TBL] [Abstract][Full Text] [Related]
4. Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset.
Channick R; Chin KM; McLaughlin VV; Lammi MR; Zamanian RT; Turricchia S; Ong R; Mitchell L; Kim NH
Cardiol Ther; 2024 Jun; 13(2):315-339. PubMed ID: 38451426
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension.
Khanna D; Gladue H; Channick R; Chung L; Distler O; Furst DE; Hachulla E; Humbert M; Langleben D; Mathai SC; Saggar R; Visovatti S; Altorok N; Townsend W; FitzGerald J; McLaughlin VV;
Arthritis Rheum; 2013 Dec; 65(12):3194-201. PubMed ID: 24022584
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
Distler O; Ofner C; Huscher D; Jordan S; Ulrich S; Stähler G; Grünig E; Held M; Ghofrani HA; Claussen M; Lange TJ; Klose H; Rosenkranz S; Vonk-Noordegraaf A; Vizza CD; Delcroix M; Opitz C; Pausch C; Scelsi L; Neurohr C; Olsson KM; Coghlan JG; Halank M; Skowasch D; Behr J; Milger K; Remppis BA; Skride A; Jureviciene E; Gumbiene L; Miliauskas S; Löffler-Ragg J; Wilkens H; Pittrow D; Hoeper MM; Ewert R
Rheumatology (Oxford); 2024 Apr; 63(4):1139-1146. PubMed ID: 37462520
[TBL] [Abstract][Full Text] [Related]
7. Early risk prediction in idiopathic
Hjalmarsson C; Kjellström B; Jansson K; Nisell M; Kylhammar D; Kavianipour M; Rådegran G; Söderberg S; Wikström G; Wuttge DM; Hesselstrand R
ERJ Open Res; 2021 Jul; 7(3):. PubMed ID: 34350280
[TBL] [Abstract][Full Text] [Related]
8. The Role of Pulmonary Function Test for Pulmonary Arterial Hypertension in Patients with Connective Tissue Disease.
Xiong J; Li J; Huang Y; Yang F; Wu R
Dis Markers; 2022; 2022():6066291. PubMed ID: 36212174
[No Abstract] [Full Text] [Related]
9. Immunosuppressive therapy in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic review.
Ding Y; Qian J; Zhang S; Xu D; Leng X; Zhao J; Wang Q; Zhang W; Tian X; Li M; Zeng X
Int J Rheum Dis; 2022 Sep; 25(9):982-990. PubMed ID: 35699128
[TBL] [Abstract][Full Text] [Related]
10. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
11. Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag.
Tsang Y; Singh R; Verma S; Panjabi S
Rheumatol Ther; 2023 Jun; 10(3):741-756. PubMed ID: 36959524
[TBL] [Abstract][Full Text] [Related]
12. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.
Chung L; Liu J; Parsons L; Hassoun PM; McGoon M; Badesch DB; Miller DP; Nicolls MR; Zamanian RT
Chest; 2010 Dec; 138(6):1383-94. PubMed ID: 20507945
[TBL] [Abstract][Full Text] [Related]
13. Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in Southern Taiwan: A Single-Center 10-Year Longitudinal Observation Cohort.
Wu CH; Lin CY; Hsu CH; Lin SH; Weng CT
Healthcare (Basel); 2021 May; 9(5):. PubMed ID: 34065585
[No Abstract] [Full Text] [Related]
14. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension.
Langleben D; Orfanos SE; Giovinazzo M; Hirsch A; Baron M; Senécal JL; Armaganidis A; Catravas JD
Arthritis Rheum; 2008 Apr; 58(4):1156-64. PubMed ID: 18383374
[TBL] [Abstract][Full Text] [Related]
15. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
[TBL] [Abstract][Full Text] [Related]
16. Retrospective cohort study of pulmonary arterial hypertension associated with connective tissue disease effect on patients' prognosis.
Huang J; An Q; Shi H; Li C; Zhang W; Wang L
Clin Rheumatol; 2023 Nov; 42(11):3131-3142. PubMed ID: 37382842
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment.
Cansu DÜ; Korkmaz C
Clin Rheumatol; 2023 Oct; 42(10):2601-2610. PubMed ID: 36396789
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD).
Tsang Y; Panjabi S; Funtanilla V; Germack HD; Gauthier-Loiselle M; Manceur AM; Liu S; Cloutier M; Lefebvre P
Pulm Circ; 2023 Apr; 13(2):e12218. PubMed ID: 37051491
[TBL] [Abstract][Full Text] [Related]
19. Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan.
Tamura Y; Kumamaru H; Inami T; Matsubara H; Hirata KI; Tsujino I; Suda R; Miyata H; Nishimura S; Sigel B; Takano M; Tatsumi K;
JACC Asia; 2022 Jun; 2(3):273-284. PubMed ID: 36338395
[TBL] [Abstract][Full Text] [Related]
20. Real-world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database.
Omura J; Kitahara K; Takano M; Idehara K; Kim SW
Pulm Circ; 2023 Jul; 13(3):e12275. PubMed ID: 37649808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
